MDM2 and Thrombocytopenia: The most common grade ≥ 3 treatment-related AEs were neutropenia (25% for monotherapy, 24% for combination therapy) and thrombocytopenia (23% for monotherapy, 22% for combination therapy).73 These phase 1 findings were the basis for the Brightline-2 phase 2a/b study (NCT05512377) of brigimadlin in patients with advanced, MDM2-amplified, TP53 wild-type BTC, pancreatic ductal adenocarcinoma, and other select solid tumors.49,74 This study has closed, and the brigimadlin development program across various oncology indications has been discontinued.